Developing Targeted Cancer Treatments

Developing targeted cancer treatments requires an in depth understanding of cancer biology, its genetic vulnerabilities, and its symbiotic interactions within the tumor microenvironment. Our team of renowned cancer biologists and expert drug developers is applying its knowledge base across these fields to develop new therapeutic candidates that address cancer with the full picture in mind.

Recent News

View the latest news and press releases from Sporos Bioventures

View all news

Apr 17, 2023

American Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy

View Presentation

Apr 17, 2023

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

SPR1-0117 is a novel isoform-selective inhibitor of TEAD1 / TEAD4 Preclinical data show inhibition of…

Mar 15, 2023

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023

HOUSTON, Texas., March 15, 2023 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos…